Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea
The review found no eligible studies for this question.
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Acyclovir probably leads to higher the proportion of participants with good or excellent rash… compared with placebo, vitamins, or no treatment (moderate certainty).
1 finding from 1 review
Minor adverse events not leading to withdrawal of treatment · pityriasis rosea
Acyclovir showed no clear difference in minor participant‐reported adverse events not requiring withdrawal… compared with placebo, vitamins, or no treatment (moderate certainty).
1 finding from 1 review
Complications · Partcipants with bladder cancer undergoing radical cystectomy (male n = 314, female n = 87; age (interquartile range) 59 to 74)Country:…
Oral nutritional supplements showed no clear difference in complications compared with multivitamin and mineral supplement (low certainty).
1 finding from 1 review
Length of hospital stay · Partcipants with bladder cancer undergoing radical cystectomy (male n = 314, female n = 87; age (interquartile range) 59 to 74)Country:…
1 finding from 1 review
All‐cause mortality · Partcipants with bladder cancer undergoing radical cystectomy (male n = 314, female n = 87; age (interquartile range) 59 to 74)Country:…
Oral nutritional supplements showed no clear difference in mortality compared with multivitamin and mineral supplement (low certainty).
1 finding from 1 review
Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · people with chronic plaque psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse events and severe adverse events · people with chronic plaque psoriasis
1 finding from 1 review
Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) · people with chronic plaque psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving PASI 75 or PGA 1 to 2 · people with chronic plaque psoriasis
It is very uncertain whether azithromycin changes proportion of participants achieving PASI 75 or PGA 1 to 2 compared with vitamin C (very low certainty).
1 finding from 1 review
Relapse · people with chronic plaque psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Erythrocyte folate concentrations (nmol/L) · health outcomes
1 finding from 1 review
Plasma folate concentrations (nmol/L) · health outcomes
1 finding from 1 review
Outcomes ( · people with cancer with thrombosis prophylaxis and central venous catheters
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
Pulmonary embolism · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in pulmonary embolism (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).
1 finding from 1 review
Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes major bleeding (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes minor bleeding (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review